Anavex Life Sciences Corp (AVXL)

[12x]

It’s true WS doesn’t buy it. That’s why SP is $8 not $80.

If SDL mean change not significant, there is nothing one can do to change that.

However, I think what the company is trying to do is to point out to the regulators that the drug has sustained improvement on a portion of patients with minimal side effects. We can argue how small that portion is and whether it’s enough to persuade FDA to approve, but it’s the best path forward (use 50mg data is better but that’s a different story for another day).